Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series

Table 1 Intraocular pressure (mmHg) throughout the 26-week trial of teprotumumab from baseline to study completion

Patient number	Baseline		1		2		3		4		5		6		7		8
Patient number	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS
1
Primary	12	14	10	10	9	13	10	10	12	9	13	13	9	10	12	12
Lateral	9	12	12	11	12	14	13	12	14	10	13	13	13	13	12	12
Upgaze	16	15	12	12	12	12	13	13	13	11	13	13	12	11	12	12
2
Primary	15	17	11	12.5	15	15	15	15
Lateral	15	14	11	11	17	17	17	16
Upgaze	20	20	17	17	24	24	17	17
3
Primary	20	20	19	19	14	15	13	10	14	15	17	18	15	15	15	15	17	17
Lateral	18.5	21	19	19	15	10	13	20	14	10	19	15	21	21	18	18	17	17
Upgaze	24	25	22.5	24	19	21	17	16	19	17	22	20	21	27	18	18	17	17
4
Primary	13	16	9	15	15	13	9	9	13	13	8	15	10	10	9	11
Lateral	19	31	24	24	18	18	17	17	19	19	18	16	15	15	11	12
Upgaze	38	56	28	28	26	14	17	17	19	19	15	18	18	18	11	16
5
Primary	7	7	7	10	14	9	15	15	11	11	12	11	10	10	10	10	4	4
Lateral	7	7	6	6	12	12	15	15	17	17	12	11	10	10	10	10	4	4
Upgaze	5	5	14	11	12	10	15	15	11	11	12	11	10	10	10	10	4	4
6
Primary	12	13	10	13	9	10	10	10	10	10	9	12	12	14	10	10
Lateral	12	12	12	15	13	14	15	15	17	13	21	19	14	14	10	13
Upgaze	12	12	11	18	13	16	14	14	14	16	10	17	12	14	10	17
7
Primary	22	22	23	22	17	13	21	16	17	17	18	15
Lateral	27	29	26	26	17	17	19	18	23	23	22	22
Upgaze	24	32	36	36	17	18	25	25	23	23	24	23
8
Primary	11	13	16	14	13	13	12	4	17	15
Lateral	13	13	19	17	16	22	9	10	22	20
Upgaze	17	15	16	20	15	16	17	10	19	18
9
Primary	17	17	11	15
Lateral	12	12	17	17
Upgaze	21	21	18	18

ISSN: 1752-1947